Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
ACTIVE_NOT_RECRUITING
Status
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
- BIOLOGICAL: Nivolumab + ipilimumab
- BIOLOGICAL: Nivolumab + ipilimumab + platinum-based chemotherapy
- BIOLOGICAL: Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy
- BIOLOGICAL: Other dual-immuno-oncology therapy with chemotherapy
Sponsor
Bristol-Myers Squibb